<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372355</url>
  </required_header>
  <id_info>
    <org_study_id>SWUEC-043/2019F</org_study_id>
    <secondary_id>WF10-19-THAI-01</secondary_id>
    <nct_id>NCT04372355</nct_id>
  </id_info>
  <brief_title>Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients</brief_title>
  <official_title>Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Srinakharinwirot University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxo Chemie(Thailand) Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Altermed Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Srinakharinwirot University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study in adult Diabetes Mellitus patients with diabetic foot ulcers and elevated HbA1c who
      will receive standard wound treatment in combination with adjuvant therapy WF10 to compare
      the change of HbA1c levels at baseline and after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, Prospective Open-labelled One Group Pretest Posttest Pilot Study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">June 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>T2DM patients with DFU and HbA1c &gt; 8.5%</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change at Week 8 in comparison to Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>The mean change of HbA1c values between Baseline (Week 0) and Week 8 after the initial WF10 treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c change at Week 12 in comparison to Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean change of HbA1c values between Baseline (Week 0) and Week 12 after the initial WF10 treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Foot Ulcer (DFU)</condition>
  <condition>Uncontrolled Diabetes With Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Chlorite-based drug WF10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WF10</intervention_name>
    <description>WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.</description>
    <arm_group_label>Chlorite-based drug WF10</arm_group_label>
    <other_name>Immunokine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Diabetes Mellitus type II

          -  Patient male or female 18-80 years old

          -  Presence of Diabetic foot ulcer/non-healed stump, starting at least 3 weeks before or
             infected wound degree 3-4

          -  HbA1c &gt; 8.5%

          -  Hematocrit &gt; 30%

        Exclusion Criteria:

          -  Kanofsky performance status &lt; 60

          -  Patient with ABI (Ankle Brachial index) &lt; 0.4

          -  Patient who receive steroid ,chemotherapeutic drug

          -  Pregnant or lactating woman

          -  Patient had a history of organ transplantation, and using immunosuppressive drug

          -  Patient with end-stage renal disease requiring hemodialysis, or history of G6PD or
             severe thalassemia, or ischemic heart disease, Congestive heart failure, Heart
             arrhythmia

          -  Patient who is participating in another clinical study or have done it in the past 30
             days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narongchai Yingsakmongkol, MD, FRCST</last_name>
    <role>Principal Investigator</role>
    <affiliation>Srinakharinwirot University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Narongchai Yingsakmongkol, MD, FRCST</last_name>
    <phone>+66-81-6302610</phone>
    <email>narongchai@g.swu.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>HRH Princess Maha Chakri Sirindhorm Medical Center</name>
      <address>
        <city>Ongkharak</city>
        <state>Nakhon Nayok</state>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narongchai Yingsakmongkol, MD, FRCST</last_name>
      <phone>+66-81-6302610</phone>
      <email>narongchai@g.swu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Chantra Tanunyutthawongse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Srinakharinwirot University</investigator_affiliation>
    <investigator_full_name>Narongchai Yingsakmongkol</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>DFU</keyword>
  <keyword>WF10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

